Abstract 217P
Background
With conditional reprogramming (CR) technique to generate continuous primary cancer cell cultures from bladder cancer patients’ urine samples, we aimed to establish a novel in vitro model by a rapid and non-invasive method to predict clinical response to anti-tumor drugs including immunotherapy and provide drug guidance for patients.
Methods
Patients included were all diagnosed with bladder cancer, among which were 54 high grade and 14 low grade. Urine and tumor samples were collected before therapeutic treatment. The overall success rate was summarized. Whole-exome sequencing (WES) and short tandem repeat (STR) analysis were utilized to confirm the authentication of CR cultures (CRCs). Dose-response measurements were used to generate drug sensitivity scores. Expression of PD-L1 on the cell surface of urine CRCs after IFN-γ treatment is evaluated with flow cytometry.
Results
The overall success rate of establishing urine CRCs was 87.2% (68/78), with 93.1% (54/58) of high grade bladder cancer, 70.0% (14/20) of low grade bladder cancer. Importantly, the in vitro drug sensitivity results of the urine-derived cells exhibited strong consistency (78%) with the clinical responses to treatment, indicating their potential for guiding patient-specific therapeutic strategies. Furthermore, we revealed that IFN-γ-stimulated PD-L1 expression on urine CRCs could predict the prognosis of bladder cancer patients and exhibited predictive value for ICI response in bladder cancer patients with a significant consistency of 88%, highlighting their clinical relevance.
Conclusions
Our study demonstrates the successful establishment of a reliable and patient-specific bladder cancer cell model derived from urine samples which serve to guide anti-tumor drugs and immunotherapeutic interventions. The findings underscore the clinical utility and translational potential of urine-derived cells for personalized bladder cancer management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital Fudan University.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract